JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2019, 68(1):3-11 | DOI: 10.36290/csf.2019.001

Plant-derived drugs and their applicaction in the anticancer therapy

Romana Blažejová1, Jan Hošek2,*
1 Ústav molekulární biologie a farmaceutické biotechnologie, Farmaceutická fakulta, Veterinární a farmaceutická univerzita Brno
2 Oddělení biologicky aktivních komplexů a molekulových magnetů, Regionální centrum pokročilých technologií a materiálů, Přírodovědecká fakulta, Univerzita Palackého, Olomouc

Nowadays, oncological diseases are one of the most common causes of untimely death. Current therapy based on synthetic chemotherapeuties has a number of side-effects, and a resistance to this type of treatment is very common. For this reason, new substances without these effects are constantly sought. In this regard, natural products appear to be a promising source of new active compounds. This review aims to introduce cytostatics inspired by natural substances that are in clinical trials or are already in common use.

Keywords: Cytostatics; clinical trials; tumour; natural compounds
Grants and funding:

Práca bola podporovaná MŠMT ČR, projekt číslo LO1305.

Received: October 29, 2018; Accepted: February 19, 2019; Published: January 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blažejová R, Hošek J. Plant-derived drugs and their applicaction in the anticancer therapy. Čes. slov. farm. 2019;68(1):3-11. doi: 10.36290/csf.2019.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Balunas M. J., Kinghorn A. D. Drug discovery from medicinal plants. Life Sci. 2005; 78, 431-441. Go to original source... Go to PubMed...
    2. Koehn F. E., Carter G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005; 4, 206-220. Go to original source... Go to PubMed...
    3. Lahlou M. The success of natural products in drug Discovery. Pharmacol. Pharm. 2013; 4, 17-31. Go to original source...
    4. Newman D. J., Cragg G. M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016; 79, 629-661. Go to original source... Go to PubMed...
    5. Hartwell J. L. Plants used against cancer: A survey (Bioactive Plants, Vol. 2). Michigan: Quarterman Publications Inc. 1984.
    6. Cragg G. M., Newman D. J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005; 100, 72-79. Go to original source... Go to PubMed...
    7. Cibikova P., Sturdikova M., Maruna M. Natural compounds of plant origin and their application in therapy of oncological diseases. Chem. Listy 2010; 104, 12-20.
    8. Singh S., Sharma B., Kanwar S. S., Kumar A. Lead phytochemicals for anticancer drug development. Front. Plant. Sci. 2016; 7, 1667. Go to original source... Go to PubMed...
    9. Pan L., Chai H. Y., Kinghorn A. D. The continuing search for antitumor agents from higher plants. Phytochem. Lett. 2010; 3, 1-8. Go to original source... Go to PubMed...
    10. Drugs.com. ELDISINE POWDER FOR SOLUTION FOR INJECTION 5.0 MG. https://www.drugs.com/uk/eldisine-powder-for-solution-for-injection-5-0-mg-leaflet.html(15.01.2019).
    11. Gregory R. K., Smith I. E. Vinorelbine - a clinical review. Brit. J. Cancer 2000; 82, 1907-1913. Go to original source... Go to PubMed...
    12. Gerullis H., Wawroschek F., Kohne C. H., Ecke T. H. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther. Adv. Urol. 2017; 9, 28-35. Go to original source... Go to PubMed...
    13. Hearn B. R., Shaw S. J., Myles D. C. Microtubule targeting agents. In: Taylor J. B., Triggle D. J. (eds.) Comprehensive Medicinal Chemistry II. Amsterdam: Elsevier Science 2007. Go to original source...
    14. Yousefzadi M., Sharifi M., Behmanesh M., Moyano E., Bonfill M., Cusido R. M., Palazon J. Podophyllotoxin: Current approaches to its biotechnological production and future challenges. Eng. Life Sci. 2010; 10, 281-292. Go to original source...
    15. Liu Y. Q., Tian J., Qian K., Zhao X. B., Morris-Natschke S. L., Yang L., Nan X., Tian X., Lee K.-H. Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents. Med. Res. Rev. 2015; 35, 1-62. Go to original source... Go to PubMed...
    16. Ojima I., Lichtenthal B., Lee S., Wang C. W., Wang X. Taxane anticancer agents: a patent perspective. Expert Opin. Ther. Pat. 2016; 26, 1-20. Go to original source... Go to PubMed...
    17. Coronel J., Cetina L., Candelaria M., Gonzalez-Fierro A., Arias D., Cantu D., Dueñas-González A. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med. Oncol. 2009; 26, 210-214. Go to original source... Go to PubMed...
    18. Chan B. A., Coward J. I. G. Chemotherapy advances in small-cell lung cancer. J. Thorac. Dis. 2013; 5, S565-S578.
    19. BioNumerik Pharmaceuticals. Karenitecin versus topotecan in patients with advanced epithelial ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT00477282 (15. 01. 2019).
    20. Rajan R., Varghese S. C., Kurup R., Gopalakrishnan R., Venkataraman R., Satheeshkumar K., Baby S. HPTLC-based quantification of camptothecin in Ophiorrhiza species of the southern Western Ghats in India. Cogent. Chemistry 2016; 2, 1275408. Go to original source...
    21. Lu S. Q., Wang J. M. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J. Hematol. Oncol. 2014; 7, 2. Go to original source... Go to PubMed...
    22. Nazha A., Kantarjian H., Cortes J., Quintas-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin. Pharmacol. 2013; 14, 1977-1986. Go to original source... Go to PubMed...
    23. Khazir J., Mir B. A., Pilcher L., Riley D. L. Role of plants in anticancer drug discovery. Phytochem. Lett. 2014; 7, 173-181. Go to original source...
    24. Alchin D. R. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol. Ther. (Heidelb.) 2014; 4, 157-164. Go to original source... Go to PubMed...
    25. Case Comprehensive Cancer Center. Combretastatin A4 phosphate in treating patients with advanced anaplastic thyroid cancer. https://clinicaltrials.gov/ct2/show/NCT00060242?term=combretastatin-A4-phosphate&rank=5 (15. 01. 2019).
    26. Garon E. B., Neidhart J. D., Gabrail N. Y., de Oliveira M. R., Balkissoon J., Kabbinavar F. A randomized Phase II trial of the tumor vascular disrupting agent CACA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Oncotargets Ther. 2016; 9, 7275-7283. Go to original source... Go to PubMed...
    27. Chase D. M., Chaplin D. J., Monk B. J. The development and use of vascular targeted therapy in ovarian cancer. Gynecol. Oncol. 2017; 145, 393-406. Go to original source... Go to PubMed...
    28. Madlambayan G. J., Meacham A. M., Hosaka K., Mir S., Jorgensen M., Scott E. W., Siemann W., Cogle C. R. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010; 116, 1539-1547. Go to original source... Go to PubMed...
    29. Li J. Z., Ke Y. B., Misra H. P., Trush M. A., Li Y. R., Zhu H., Jia Z. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent. Toxicol. Appl. Pharmacol. 2014; 281, 285-293. Go to original source... Go to PubMed...
    30. Bey E. A., Bentle M. S., Reinicke K. E., Dong Y., Yang C. R., Girard L., Minna J. D., Bornmann W. G., Gao J., Boothman D. A. An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. PNAS 2007; 104, 11832-11837. Go to original source... Go to PubMed...
    31. Sun Y. Y., Xun K. L., Wang Y. T., Chen X. P. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anti-Cancer Drug 2009; 20, 757-769. Go to original source... Go to PubMed...
    32. Liu C. H., Tang W. C., Sia P., Huang C. C., Yang P. M., Wu M. H., Lai I. L., Lee K. H. berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT) - Associated Genes with Predictive and Prognostic Relevance. Int. J. Med. Sci. 2015; 12, 63-71. Go to original source... Go to PubMed...
    33. Chu S. C., Yu C. C., Hsu L. S., Chen K. S., Su M. Y., Chen P. N. Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor -induced angiogenesis in human cervical cancer cells. Mol. Pharmacol. 2014; 86, 609-623. Go to original source... Go to PubMed...
    34. Bao J. L., Huang B. R., Zou L. D., Chen S. H., Zhang C., Zhang Y. L., Chen M., Wan J.-B., Su H., Wang Y., He C. Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents. PLOS One 2015; 10, e0139298. Go to original source... Go to PubMed...
    35. Liu Q., Jiang H. Y., Liu Z. J., Wang Y., Zhao M. N., Hao C. Y., Feng S., Guo H., Xu B., Yang Q., Gong Y., Shao C. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLOS One. 2011; 6, e23427. Go to original source... Go to PubMed...
    36. Najmi S., Korah R., Chandra R., Abdellatif M., Wieder R. Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin. Cancer Res. 2005; 11, 2038-2046. Go to original source... Go to PubMed...
    37. Kelland L. R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert. Opin. Inv. Drug 2000; 9, 2903-2911. Go to original source... Go to PubMed...
    38. Wang L. M., Ren D. M. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini-Rev. Med. Chem. 2010; 10, 1058-1070. Go to original source... Go to PubMed...
    39. Hirose K., Imaeda N., Tokudome Y., Goto C., Wakai K., Matsuo K., Ito H., Toyama T., Iwata H., Tokudome S., Tajima K. Soybean products and reduction of breast cancer risk: a case control study in Japan. Brit. J. Cancer 2005; 93, 15-22. Go to original source... Go to PubMed...
    40. Perabo F. G. E., Von Low E. C., Ellinger J., Von Rucker A., Muller S. C., Bastian P. J. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11, 6-12. Go to original source... Go to PubMed...
    41. Sarkar F. H., Li Y. W. The role of isoflavones in cancer chemoprevention. Front. Biosci.-Landmrk. 2004; 9, 2714-2724. Go to original source... Go to PubMed...
    42. Schnekenburger M., Diederich M. Nutritional epigenetic regulators in the field of cancer: new avenues for chemopreventive approaches. In: Gray S. G. (ed.) Epigenetic Cancer Therapy. London: Academic Press 2015. Go to original source...
    43. Spagnuolo C., Russo G. L., Orhan I. E., Habtemariam S., Daglia M., Sureda A., Nabavi S. F., Devi K. P., Loizzo M. R., Tundis R., Nabavi S. M. Genistein and cancer: current status, challenges, and future directions. Adv. Nutr. 2015; 6, 408-419. Go to original source... Go to PubMed...
    44. Mishra B. B., Tiwari V. K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem. 2011; 46, 4769-807. Go to original source... Go to PubMed...
    45. Pyne N. J., Tonelli F., Lim K. G., Long J. S., Edwards J., Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem. Soc. Trans. 2012; 40, 94-100. Go to original source... Go to PubMed...
    46. Gamble J. R., Xia P., Hahn C. N., Drew J. J., Drogemuller C. J., Brown D., Vadas M. A. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int. J. Cancer 2006; 118, 2412-2420. Go to original source... Go to PubMed...
    47. Georgaki S., Skopeliti M., Tsiatas M., Nicolaou K. A., Ioannou K., Husband A., Bamias A., Dimopoulos M. A., Constantinou A. I., Tsitsilonis O. E. Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. J. Cell. Mol. Med. 2009; 13, 3929-3938. Go to original source... Go to PubMed...
    48. Fotopoulou C., Vergote I., Mainwaring P., Bidzinski M., Vermorken J. B., Ghamande S. A., Harnett P., Del Prete S. A., Green J. A., Spaczynski M., Blagden S., Gore M., Ledermann J., Kaye S., Gabra H. Weekly AUC2 carboplatin in acquired platinum resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase Ill OVATURE multicenter randomized study. Ann. Oncol. 2014; 25, 160-165. Go to original source... Go to PubMed...
    49. Xiong J., Li J. S., Yang Q., Wang J., Su T. F., Zhou S. Gossypol has anti-cancer effects by dual targeting MDM2 and VEGF in human breast cancer. Breast Cancer Res. 2017; 19, 27. Go to original source... Go to PubMed...
    50. Meng Y., Tang W. H., Dai Y., Wu X. Q., Liu M. L., Ji Q., Ji M., Pienta K., Lawrence T., Xu L. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol. Cancer Ther. 2008; 7, 2192-2202. Go to original source... Go to PubMed...
    51. Bimonte S., Barbieri A., Leongito M., Piccirillo M., Giudice A., Pivonello C., de Angelis C., Granata V., Palaia R., Izzo F. Curcumin anticancer studies in pancreatic cancer. Nutrients 2016; 8, E433 Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.